

Demographic Data		Clinical Data		Laboratory Data		Treatment Data		Outcome Data	
Variable	Value	Variable	Value	Variable	Value	Variable	Value	Variable	Value
Age (years)	65.2	Sex (Male/Female)	45/20	Weight (kg)	78.5	Height (cm)	175.3	BMI (kg/m²)	25.8
Duration of illness (years)	12.5	Previous hospitalizations	5	Current medications	Insulin, Metoprolol, Aspirin				
Family history of diabetes	Yes	Smoking status	Former	Alcohol consumption	Occasional				
Comorbidities	Hypertension, Hyperlipidemia								
Initial HbA1c (%)	8.5	Initial Fasting Glucose (mg/dL)	180	Initial Postprandial Glucose (mg/dL)	220				
Initial C-peptide (ng/mL)	0.5	Initial Insulin Sensitivity Index	0.001						
Initial HbA1c (%)	7.8	Initial Fasting Glucose (mg/dL)	150	Initial Postprandial Glucose (mg/dL)	180				
Initial C-peptide (ng/mL)	0.6	Initial Insulin Sensitivity Index	0.002						
Initial HbA1c (%)	7.2	Initial Fasting Glucose (mg/dL)	120	Initial Postprandial Glucose (mg/dL)	150				
Initial C-peptide (ng/mL)	0.7	Initial Insulin Sensitivity Index	0.003						
Initial HbA1c (%)	6.8	Initial Fasting Glucose (mg/dL)	100	Initial Postprandial Glucose (mg/dL)	130				
Initial C-peptide (ng/mL)	0.8	Initial Insulin Sensitivity Index	0.004						
Initial HbA1c (%)	6.5	Initial Fasting Glucose (mg/dL)	90	Initial Postprandial Glucose (mg/dL)	120				
Initial C-peptide (ng/mL)	0.9	Initial Insulin Sensitivity Index	0.005						
Initial HbA1c (%)	6.2	Initial Fasting Glucose (mg/dL)	80	Initial Postprandial Glucose (mg/dL)	110				
Initial C-peptide (ng/mL)	1.0	Initial Insulin Sensitivity Index	0.006						
Initial HbA1c (%)	6.0	Initial Fasting Glucose (mg/dL)	70	Initial Postprandial Glucose (mg/dL)	100				
Initial C-peptide (ng/mL)	1.1	Initial Insulin Sensitivity Index	0.007						
Initial HbA1c (%)	5.8	Initial Fasting Glucose (mg/dL)	60	Initial Postprandial Glucose (mg/dL)	90				
Initial C-peptide (ng/mL)	1.2	Initial Insulin Sensitivity Index	0.008						
Initial HbA1c (%)	5.5	Initial Fasting Glucose (mg/dL)	50	Initial Postprandial Glucose (mg/dL)	80				
Initial C-peptide (ng/mL)	1.3	Initial Insulin Sensitivity Index	0.009						
Initial HbA1c (%)	5.2	Initial Fasting Glucose (mg/dL)	40	Initial Postprandial Glucose (mg/dL)	70				
Initial C-peptide (ng/mL)	1.4	Initial Insulin Sensitivity Index	0.010						
Initial HbA1c (%)	5.0	Initial Fasting Glucose (mg/dL)	30	Initial Postprandial Glucose (mg/dL)	60				
Initial C-peptide (ng/mL)	1.5	Initial Insulin Sensitivity Index	0.011						
Initial HbA1c (%)	4.8	Initial Fasting Glucose (mg/dL)	20	Initial Postprandial Glucose (mg/dL)	50				
Initial C-peptide (ng/mL)	1.6	Initial Insulin Sensitivity Index	0.012						
Initial HbA1c (%)	4.5	Initial Fasting Glucose (mg/dL)	10	Initial Postprandial Glucose (mg/dL)	40				
Initial C-peptide (ng/mL)	1.7	Initial Insulin Sensitivity Index	0.013						
Initial HbA1c (%)	4.2	Initial Fasting Glucose (mg/dL)	5	Initial Postprandial Glucose (mg/dL)	30				
Initial C-peptide (ng/mL)	1.8	Initial Insulin Sensitivity Index	0.014						
Initial HbA1c (%)	4.0	Initial Fasting Glucose (mg/dL)	0	Initial Postprandial Glucose (mg/dL)	20				
Initial C-peptide (ng/mL)	1.9	Initial Insulin Sensitivity Index	0.015						
Initial HbA1c (%)	3.8	Initial Fasting Glucose (mg/dL)	0	Initial Postprandial Glucose (mg/dL)	10				
Initial C-peptide (ng/mL)	2.0	Initial Insulin Sensitivity Index	0.016						
Initial HbA1c (%)	3.5	Initial Fasting Glucose (mg/dL)	0	Initial Postprandial Glucose (mg/dL)	0				
Initial C-peptide (ng/mL)	2.1	Initial Insulin Sensitivity Index	0.017						
Initial HbA1c (%)	3.2	Initial Fasting Glucose (mg/dL)	0	Initial Postprandial Glucose (mg/dL)	0				
Initial C-peptide (ng/mL)	2.2	Initial Insulin Sensitivity Index	0.018						
Initial HbA1c (%)	3.0	Initial Fasting Glucose (mg/dL)	0	Initial Postprandial Glucose (mg/dL)	0				
Initial C-peptide (ng/mL)	2.3	Initial Insulin Sensitivity Index	0.019						
Initial HbA1c (%)	2.8	Initial Fasting Glucose (mg/dL)	0	Initial Postprandial Glucose (mg/dL)	0				
Initial C-peptide (ng/mL)	2.4	Initial Insulin Sensitivity Index	0.020						
Initial HbA1c (%)									

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Duncan W. McBRANCH, et al. ART UNIT:
SERIAL NO.: New Application EXAMINER:
FILING DATE: Herewith
FOR: PEPTIDE NUCLEIC ACID BASED MOLECULAR SENSORS FOR
 NUCLEIC ACIDS

LIST OF INVENTORS' NAMES AND ADDRESSES

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Listed below are the names and addresses of the inventors for the above-identified patent application.

- 1) Duncan W. McBRANCH
14 North Sparrow Lane
Sante Fe, New Mexico 87501
- 2) David G. WHITTEN
811 D. West Manhattan Avenue
Sate Fe, New Mexico 87501
- 3) Michael Egholm
8 Dogwood Court
Woodbridge, Connecticut 06525

A declaration containing all the necessary information will be submitted at a later date.

Respectfully submitted,

PIPER MARBURY RUDNICK & WOLFE LLP

Angie Miller

Steven B. Kelber
Registration No. 30,073
Attorney of Record

1200 Nineteenth Street, N.W.
Washington, D.C. 20036-2412
Telephone No. (202) 861-3900
Facsimile No. (202) 223-2085

Amy L. Miller
Registration No. 43,804